Review: The Role of Hyperthermia in Treating Pancreatic Tumors

被引：10

作者：

Roesch M. ^{[1
,2
]}

Mueller-Huebenthal B. ^{[1
,2
]}

机构：

[1] Research & Development Celsius42+, Mannheim

[2] Oncology, Paracelsus Klinik, Zurich-Richterswil

来源：

Indian Journal of Surgical Oncology | 2015年 / 6卷 / 1期

关键词：

Adjuvant heat treatment; Hyperthermia; Palliative pain reduction; Pancreatic cancer;

D O I：

10.1007/s13193-014-0316-5

中图分类号：

学科分类号：

摘要：

There is only marginal improvement in outcome of treating pancreatic cancer in the last two decades. Time to open up and have a fresh look at complementary adjuvant treatment options. Hyperthermia may be one such option. Hyperthermic intraperitoneal chemotherapy (HIPEC) predominantly as a intrasurgical procedure has already proved its justification. Non-invasive loco regional hyperthermia as complement to either chemo or radiation has not yet reached a comparable status of evidence. However the potential to eventually grow into such evidence is already clearly observable. This review presents the various methodologies available for hyperthermia, covers the initial clinical data that has been published and gives an outlook to what can be expected in the next 2–3 years to come. Hyperthermia has the potential to significantly prolong life expectancies and this while maintaining a satisfying quality of life! © 2014, Indian Association of Surgical Oncology.

引用

页码：75 / 81

页数：6

共 36 条

[1]

Burris H.A., Moore M.J., Andersen J., Et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, 15, 6, pp. 2403-2413, (1997)

[2]

Riess H., Helm A., Niedergethmann M., A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer, Proc. ASCO

[3]

Abstr No, (2005)

[4]

Conroy T., Desseigne F., Ychou M., Et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 19, pp. 1817-1825, (2011)

[5]

Bakshandeh-Bath A., Stoltz A.S., Homann N., Wagner T., Stolting S., Peters S.O., Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma, Anticancer Res, 29, 8, pp. 3069-3077, (2009)

[6]

Yamada S., Takai Y., Nemoto K., Ogawa Y., Kakuto Y., Hoshi A., Sakamoto K., Kimura Y., Kobari M., Intraoperative radiation therapy combined with hyperthermia against pancreatic carcinoma, Int J Oncol, 1, 7, pp. 795-798, (1992)

[7]

Kouloulias V.E., Kouvaris J.R., Nikita K.S., Golematis B.C., Uzunoglu N.K., Mystakidou K., Papavasiliou C., Vlahos L., Intraoperative hyperthermia in conjunction with multi-schedule chemotherapy (pre-, intra- and post-operative), by-pass surgery, and post-operative radiotherapy for the management of unresectable pancreatic adenocarcinoma, Int J Hyperth, 18, 3, pp. 233-252, (2002)

[8]

Nakagawa A., Kamiyama Y., Matsui Y., Okuno M., Imamura A., Tu W., Nakagawa M., Kanemaki T., Takai S., Uetsuji S., Noro C., Kubo N., Nakase Y., Selective thermocoagulation of unresectable malignant tumors using radiofrequency [Article in Japanese], RiGan To Kagaku Ryoho, 23, 12, pp. 1651-1653, (1996)

[9]

Sugarbaker P.H., Stuart O.A., Bijelic L., Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data, Int J Surg Oncol, 2011, (2011)

[10]

Esquivel J., Et al., Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement, Ann Surg Oncol, (2006)

← 1 2 3 4 →